HOME › Press Releases › Biochips Market worth 17.75 Billion USD by 2020
Biochips Market worth 17.75 Billion USD by 2020
The report “Biochips Market by Type (DNA Chip (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), Protein Chips), End user (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast to 2020”, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the biochips market along with the estimates and forecasts of the revenue.
Browse 76 market data Tables and 69 Figures spread through 170 Pages and in-depth TOC on "Biochips Market by Type (DNA Chip (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), Protein Chips), End user (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast to 2020"
Early buyers will receive 10% customization on reports.
The biochips market is expected to reach USD 17.75 Billion by 2020 from USD 7.63 Billion in 2015, growing at a CAGR of 18.4% during the forecast period (2015–2020).
Increasing adoption of personalized medicine, growing applications of biochips, and technological advancements are the major drivers for the biochips market. However, unclear regulatory guidelines, high instrumentation costs, and absolute quantification of specific mRNA may restrain the market growth to a certain extent.
In this report, the biochips market is segmented on the basis of type, application, fabrication technology, end user, and region. Based on type, the market is segmented into DNA chips, lab-on-a-chip, protein chips, and other arrays. The other arrays segment includes cell arrays and tissue arrays. Based on applications, the DNA chips segment is categorized into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, agricultural biotechnology, drug discovery, and other applications (microbial genotyping, proteomics, toxicogenomics, screening and monitoring of patient data in clinical trials, and environmental biology). Based on applications, the lab-on-a-chip segment is classified into genomics, proteomics, drug discovery, IVD & POC clinical diagnostics, and other applications (biodefense, food pathogen identification, and environmental contamination). Similarly, the protein chips market, by application, is segmented into proteomics, high-throughput screening, drug discovery, and other applications (environmental diagnostics and biodefense).
Based on end users, the biochips market is categorized into four major segments, namely, hospitals & diagnostic centers, biotechnology & pharmaceutical companies, academic & research institutes, and other end users (blood banks, CROs, forensic labs, point-of-care settings, home health agencies, nursing homes, and local public health laboratories). Similarly, based on fabrication technology, the biochips market is segmented into microarrays and microfluidics.
North America accounted for the largest share of the biochips market in 2015. The large share of this regional segment can majorly be attributed to the rising geriatric population; increasing prevalence of lifestyle diseases, such as diabetes, asthma, and cardiac disorders; growing adoption of biochips; and a significant number of ongoing research activities and discoveries related to biochips in the North American region. In addition, major local companies have easy access to this market, which makes it the largest and most significant market for suppliers. Asia-Pacific, on the other hand, is expected to grow at the highest CAGR over the next five years.
Abbott Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer Inc. (U.S.), Fluidigm Corporation (U.S.), Illumina, Inc. (U.S.), GE Healthcare (U.S.), Bio-Rad Laboratories Inc. (U.S.), Cepheid Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland) are the major players in the biochips market.
MarketsandMarkets is the world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India